MARKET

ASND

ASND

Ascendis Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

88.72
-1.58
-1.75%
After Hours: 88.72 0 0.00% 16:00 05/26 EDT
OPEN
90.54
PREV CLOSE
90.30
HIGH
92.48
LOW
88.01
VOLUME
451.66K
TURNOVER
0
52 WEEK HIGH
178.71
52 WEEK LOW
61.58
MARKET CAP
5.05B
P/E (TTM)
-9.9650
1D
5D
1M
3M
1Y
5Y
Ascendis Pharma Reports Results From Co. Investment, VISEN Pharma's Phase 3 Trial Of TransCon In China, Results Consistent With Ascendis Pharma's Trial
   VISEN’s Phase 3 Trial achieved primary endpoint; pediatric growth hormone deficiency (GHD) patients treated with TransCon™ hGH demonstrated greater annualized height velocity at 52-weeks
Benzinga · 3d ago
Positive Results from VISEN’s Phase 3 Trial of Once-Weekly TransCon hGH in China Consistent with Ascendis Pharma’s Phase 3 Height Trial
- VISEN’s Phase 3 Trial achieved primary endpoint; pediatric growth hormone deficiency (GHD) patients treated with TransCon™ hGH demonstrated greater annualized height velocity at 52-weeks (p=0.0010) compared to patients treated with daily growth hormone -...
GlobeNewswire · 3d ago
Ascendis Pharma A/S Announces New Commercial Endocrinology Leadership Appointments
- Joe Kelly has been appointed to the newly created role of Head of U.S. Commercial, Endocrinology - Scott A. Holmes has been appointed to the newly created role of Head of Global Commercial Strategy, Endocrinology - Jesper Høiland, Global Chief Commercial...
GlobeNewswire · 3d ago
Ascendis, Visen' TransCon hGH meets main goal in growth hormone deficiency China trial in children
Ascendis Pharma (ASND) and Visen Pharmaceuticals' lonapegsomatropin (TransCon hGH) showed to be better than a daily human growth hormone (hGH) in a phase 3 trial in children with growth hormone deficiency (GHD)
Seekingalpha · 3d ago
--Berenberg Bank Adjusts Ascendis Pharma's Price Target to $168 From $192, Maintains Buy Rating
MT Newswires · 05/16 07:26
What 14 Analyst Ratings Have To Say About Ascendis Pharma
Within the last quarter, Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings:
Benzinga · 05/12 21:06
Ascendis Pharma stock falls as 5 firms cut price target after Q1 results
Ascendis Pharma (ASND) stock fell ~5% on May 12 after five firms lowered their price target on the stock following Q1 results. Wells Fargo cut its price target on ASND to
Seekingalpha · 05/12 17:30
Ascendis Pharma slides after Street analysts cut price target over SKYTROFA revenue miss
Ascendis Pharma (ASND -4.2%) fell sharply likely in reaction to Dovish biotech's earnings report that got the Wall Street's analysts off the ground to lower their price target over SKYTROFA cautious outlook. 
Seekingalpha · 05/12 17:21
More
No Data
Learn about the latest financial forecast of ASND. Analyze the recent business situations of Ascendis Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 15 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

46.67%Strong Buy
46.67%Buy
6.67%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ASND stock price target is 154.79 with a high estimate of 209.52 and a low estimate of 88.72.
High209.52
Average154.79
Low88.72
Current 88.72
EPS
Actual
Estimate
-2.37-1.78-1.18-0.59
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 245
Institutional Holdings: 74.30M
% Owned: 130.44%
Shares Outstanding: 56.96M
TypeInstitutionsShares
Increased
64
4.13M
New
28
870.14K
Decreased
58
1.07M
Sold Out
23
344.92K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.99%
Pharmaceuticals & Medical Research
+0.43%
Key Executives
Non-Executive Chairman/Independent Director
Albert Cha
President/Chief Executive Officer/Executive Director/Executive Board
Jan Moller Mikkelsen
Chief Financial Officer/Senior Vice President/Executive Board/IR Contact Officer
Scott Smith
Senior Vice President/Chief Administrative Officer/Executive Board
Lotte Soenderbjerg
Senior Vice President/Executive Board
Michael Jensen
Senior Vice President
Vibeke Breinholt
Senior Vice President
Jesper Hoiland
Senior Vice President
Flemming Jensen
Senior Vice President
Jens Okkels
Senior Vice President
Dana Pizzuti
Senior Vice President
Juha Punnonen
Senior Vice President
Stina Singel
Senior Vice President
Kennett Sprogoee
Senior Vice President
Birgitte Volck
Chief Accounting Officer/Vice President - Finance
Peter Rasmussen
Independent Director
Lisa Bright
Independent Director
James Healy
Independent Director
Lars Holtug
Independent Director
Rafaele Tordjman
No Data
No Data
About ASND
ASCENDIS PHARMA A/S is a Danish-based biopharmaceutical company, which is involved in manufacture products for rare diseases. The Company utilizes its TransCon technologies for treatment, which can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs. The Company is headquartered in Copenhagen, Denmark with offices in Heidelberg, Germany and Palo Alto, California.

Webull offers kinds of Ascendis Pharma A/S stock information, including NASDAQ:ASND real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ASND stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ASND stock methods without spending real money on the virtual paper trading platform.